- SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launchSK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.Fierce Biotech · 11h ago↗ source
- Neumora Therapeutics appoints Joshua Pinto as CEO and Doron Sagman as CMO ahead of IND filingNeumora Therapeutics announced leadership changes, naming Joshua Pinto, Ph.D., as its new chief executive officer. Pinto, who joined Neumora in 2021 as chief financial officer and most recently se…
- FDA clears Lantheus' Tauklarify PET imaging agent for Alzheimer’s tau detection